NCT06161025 2026-01-12
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
Clinical Trials
10 trialsNCT07219238 2025-10-21
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare
Phase 2/3 Not yet recruiting
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT06211023 2024-01-18
A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2/3 Not yet recruiting
NCT02490488 2020-12-08
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
AB Science
Phase 2/3 Completed
NCT00443196 2018-03-12
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Pierian Biosciences
Phase 2/3 Completed
NCT00003880 2015-04-16
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00327444 2013-01-01
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Sanofi
Phase 2/3 Completed
NCT00243685 2012-01-26
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Pierian Biosciences
Phase 2/3 Completed
NCT00418574 2011-11-24
MIMOSA
Menarini Group
Phase 2/3 Terminated